Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

  1. De Santis, M.
  2. Breijo, S.M.
  3. Robinson, P.
  4. Capone, C.
  5. Pascoe, K.
  6. Van Sanden, S.
  7. Hashim, M.
  8. Trevisan, M.
  9. Daly, C.
  10. Reitsma, F.
  11. van Beekhuizen, S.
  12. Ruan, H.
  13. Heeg, B.
  14. Verzoni, E.
Revista:
Advances in Therapy

ISSN: 1865-8652,  0741-238X

Ano de publicación: 2024

Tipo: Revisión

DOI: 10.1007/S12325-024-02918-6 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus